Gyre Therapeutics (NASDAQ:GYRE) Shares Down 3.2% – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price traded down 3.2% on Monday . The stock traded as low as $10.41 and last traded at $10.44. 45,861 shares traded hands during mid-day trading, a decline of 53% from the average session volume of 97,472 shares. The stock had previously closed at $10.79.

Gyre Therapeutics Stock Performance

The firm has a 50 day simple moving average of $12.30 and a 200-day simple moving average of $12.67.

Insider Activity at Gyre Therapeutics

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the sale, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 12,941 shares of company stock worth $153,041. Company insiders own 19.52% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors have recently modified their holdings of the company. FMR LLC purchased a new stake in Gyre Therapeutics during the 3rd quarter worth about $47,000. Barclays PLC lifted its stake in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares during the last quarter. Rhumbline Advisers acquired a new position in Gyre Therapeutics in the second quarter valued at approximately $123,000. Renaissance Technologies LLC purchased a new position in Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, Bank of New York Mellon Corp acquired a new stake in Gyre Therapeutics during the second quarter worth approximately $218,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.